AU688029B2 - An equilin double bond isomer from the acid isomerization of equilin - Google Patents
An equilin double bond isomer from the acid isomerization of equilin Download PDFInfo
- Publication number
- AU688029B2 AU688029B2 AU22421/95A AU2242195A AU688029B2 AU 688029 B2 AU688029 B2 AU 688029B2 AU 22421/95 A AU22421/95 A AU 22421/95A AU 2242195 A AU2242195 A AU 2242195A AU 688029 B2 AU688029 B2 AU 688029B2
- Authority
- AU
- Australia
- Prior art keywords
- document
- international
- dehydro
- bone
- isoestrone
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- WKRLQDKEXYKHJB-HFTRVMKXSA-N equilin Chemical compound OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 WKRLQDKEXYKHJB-HFTRVMKXSA-N 0.000 title claims description 16
- WKRLQDKEXYKHJB-UHFFFAOYSA-N Equilin Natural products OC1=CC=C2C3CCC(C)(C(CC4)=O)C4C3=CCC2=C1 WKRLQDKEXYKHJB-UHFFFAOYSA-N 0.000 title claims description 15
- 239000002253 acid Substances 0.000 title claims description 4
- 238000006317 isomerization reaction Methods 0.000 title description 4
- 238000000034 method Methods 0.000 claims abstract description 30
- 208000006386 Bone Resorption Diseases 0.000 claims abstract description 26
- 230000024279 bone resorption Effects 0.000 claims abstract description 26
- 241001465754 Metazoa Species 0.000 claims abstract description 19
- 238000002360 preparation method Methods 0.000 claims abstract description 11
- 230000008569 process Effects 0.000 claims abstract description 10
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 8
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 7
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 4
- 150000001875 compounds Chemical class 0.000 claims description 28
- 238000011282 treatment Methods 0.000 claims description 26
- 150000003839 salts Chemical class 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 9
- 230000000694 effects Effects 0.000 claims description 8
- 230000011164 ossification Effects 0.000 claims description 6
- 150000003431 steroids Chemical class 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 241000282414 Homo sapiens Species 0.000 claims description 4
- 239000000262 estrogen Substances 0.000 claims description 4
- 229940011871 estrogen Drugs 0.000 claims description 3
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 208000029078 coronary artery disease Diseases 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims 3
- OPRAONAUWNNOOV-UHFFFAOYSA-N Boschniakin Natural products C1=NC=C(C=O)C2=C1C(C)CC2 OPRAONAUWNNOOV-UHFFFAOYSA-N 0.000 claims 1
- 230000001419 dependent effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 230000003859 lipid peroxidation Effects 0.000 claims 1
- 230000004060 metabolic process Effects 0.000 claims 1
- 210000000988 bone and bone Anatomy 0.000 abstract description 49
- 238000004519 manufacturing process Methods 0.000 abstract description 8
- 208000001132 Osteoporosis Diseases 0.000 description 19
- 239000011575 calcium Substances 0.000 description 18
- 241000700159 Rattus Species 0.000 description 16
- 239000002609 medium Substances 0.000 description 14
- 239000000243 solution Substances 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- 229940079593 drug Drugs 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 229910052791 calcium Inorganic materials 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000004817 gas chromatography Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 210000002303 tibia Anatomy 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 206010065687 Bone loss Diseases 0.000 description 5
- 238000005481 NMR spectroscopy Methods 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 210000000689 upper leg Anatomy 0.000 description 5
- -1 11-substituted 1,3,5(10)-estratrienes Chemical class 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
- 102000003982 Parathyroid hormone Human genes 0.000 description 4
- 108090000445 Parathyroid hormone Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000007900 aqueous suspension Substances 0.000 description 4
- 230000010256 bone deposition Effects 0.000 description 4
- 210000003557 bones of lower extremity Anatomy 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 229910052500 inorganic mineral Inorganic materials 0.000 description 4
- 235000010755 mineral Nutrition 0.000 description 4
- 239000011707 mineral Substances 0.000 description 4
- 230000001009 osteoporotic effect Effects 0.000 description 4
- 239000000199 parathyroid hormone Substances 0.000 description 4
- 229960001319 parathyroid hormone Drugs 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 230000003595 spectral effect Effects 0.000 description 4
- SONVSJYKHAWLHA-HTWSVDAQSA-N (13s)-3-hydroxy-13-methyl-7,8,12,14,15,16-hexahydro-6h-cyclopenta[a]phenanthren-17-one Chemical compound OC1=CC=C2C3=CC[C@](C)(C(CC4)=O)C4C3CCC2=C1 SONVSJYKHAWLHA-HTWSVDAQSA-N 0.000 description 3
- 102000055006 Calcitonin Human genes 0.000 description 3
- 108060001064 Calcitonin Proteins 0.000 description 3
- 206010017076 Fracture Diseases 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 238000009835 boiling Methods 0.000 description 3
- 229960004015 calcitonin Drugs 0.000 description 3
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000003610 charcoal Substances 0.000 description 3
- 239000012043 crude product Substances 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 210000003754 fetus Anatomy 0.000 description 3
- 238000002372 labelling Methods 0.000 description 3
- 238000001819 mass spectrum Methods 0.000 description 3
- 238000002844 melting Methods 0.000 description 3
- 230000008018 melting Effects 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 238000004810 partition chromatography Methods 0.000 description 3
- 208000028169 periodontal disease Diseases 0.000 description 3
- 229940124531 pharmaceutical excipient Drugs 0.000 description 3
- 238000000554 physical therapy Methods 0.000 description 3
- 238000011533 pre-incubation Methods 0.000 description 3
- 238000001228 spectrum Methods 0.000 description 3
- 230000000153 supplemental effect Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- 101150041968 CDC13 gene Proteins 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- 238000001061 Dunnett's test Methods 0.000 description 2
- 229920013685 Estron Polymers 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-N Fluorane Chemical compound F KRHYYFGTRYWZRS-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 208000029725 Metabolic bone disease Diseases 0.000 description 2
- 206010030247 Oestrogen deficiency Diseases 0.000 description 2
- 206010049088 Osteopenia Diseases 0.000 description 2
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 2
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- 229930003316 Vitamin D Natural products 0.000 description 2
- QYSXJUFSXHHAJI-XFEUOLMDSA-N Vitamin D3 Natural products C1(/[C@@H]2CC[C@@H]([C@]2(CCC1)C)[C@H](C)CCCC(C)C)=C/C=C1\C[C@@H](O)CCC1=C QYSXJUFSXHHAJI-XFEUOLMDSA-N 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- NOSIYYJFMPDDSA-UHFFFAOYSA-N acepromazine Chemical compound C1=C(C(C)=O)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 NOSIYYJFMPDDSA-UHFFFAOYSA-N 0.000 description 2
- 229960005054 acepromazine Drugs 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 230000008468 bone growth Effects 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000002638 denervation Effects 0.000 description 2
- CFCUWKMKBJTWLW-UHFFFAOYSA-N deoliosyl-3C-alpha-L-digitoxosyl-MTM Natural products CC=1C(O)=C2C(O)=C3C(=O)C(OC4OC(C)C(O)C(OC5OC(C)C(O)C(OC6OC(C)C(O)C(C)(O)C6)C5)C4)C(C(OC)C(=O)C(O)C(C)O)CC3=CC2=CC=1OC(OC(C)C1O)CC1OC1CC(O)C(O)C(C)O1 CFCUWKMKBJTWLW-UHFFFAOYSA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 150000002159 estradiols Chemical class 0.000 description 2
- 238000009164 estrogen replacement therapy Methods 0.000 description 2
- 150000002167 estrones Chemical class 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013355 food flavoring agent Nutrition 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- 229910000040 hydrogen fluoride Inorganic materials 0.000 description 2
- 239000005457 ice water Substances 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 229960003299 ketamine Drugs 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- CFCUWKMKBJTWLW-BKHRDMLASA-N mithramycin Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BKHRDMLASA-N 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 229960003171 plicamycin Drugs 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000003497 sciatic nerve Anatomy 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- PUZPDOWCWNUUKD-UHFFFAOYSA-M sodium fluoride Chemical compound [F-].[Na+] PUZPDOWCWNUUKD-UHFFFAOYSA-M 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000012453 sprague-dawley rat model Methods 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- XREXPQGDOPQPAH-QKUPJAQQSA-K trisodium;[(z)-18-[1,3-bis[[(z)-12-sulfonatooxyoctadec-9-enoyl]oxy]propan-2-yloxy]-18-oxooctadec-9-en-7-yl] sulfate Chemical compound [Na+].[Na+].[Na+].CCCCCCC(OS([O-])(=O)=O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(CCCCCC)OS([O-])(=O)=O)COC(=O)CCCCCCC\C=C/CC(CCCCCC)OS([O-])(=O)=O XREXPQGDOPQPAH-QKUPJAQQSA-K 0.000 description 2
- 210000001364 upper extremity Anatomy 0.000 description 2
- 235000019166 vitamin D Nutrition 0.000 description 2
- 239000011710 vitamin D Substances 0.000 description 2
- 150000003710 vitamin D derivatives Chemical class 0.000 description 2
- 229940046008 vitamin d Drugs 0.000 description 2
- SONVSJYKHAWLHA-UHFFFAOYSA-N (-3-Hydroxyestra-1,3,5(10),9(11)-tetraen-17-one Natural products OC1=CC=C2C3=CCC(C)(C(CC4)=O)C4C3CCC2=C1 SONVSJYKHAWLHA-UHFFFAOYSA-N 0.000 description 1
- 229920002818 (Hydroxyethyl)methacrylate Polymers 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 235000003911 Arachis Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 206010003497 Asphyxia Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 208000004434 Calcinosis Diseases 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- OYPRJOBELJOOCE-BKFZFHPZSA-N Calcium-45 Chemical compound [45Ca] OYPRJOBELJOOCE-BKFZFHPZSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- FMTDIUIBLCQGJB-UHFFFAOYSA-N Demethylchlortetracyclin Natural products C1C2C(O)C3=C(Cl)C=CC(O)=C3C(=O)C2=C(O)C2(O)C1C(N(C)C)C(O)=C(C(N)=O)C2=O FMTDIUIBLCQGJB-UHFFFAOYSA-N 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- BFPYWIDHMRZLRN-SLHNCBLASA-N Ethinyl estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@](CC4)(O)C#C)[C@@H]4[C@@H]3CCC2=C1 BFPYWIDHMRZLRN-SLHNCBLASA-N 0.000 description 1
- 206010016454 Femur fracture Diseases 0.000 description 1
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000033830 Hot Flashes Diseases 0.000 description 1
- 206010060800 Hot flush Diseases 0.000 description 1
- 206010020584 Hypercalcaemia of malignancy Diseases 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- 102000000589 Interleukin-1 Human genes 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 206010028813 Nausea Diseases 0.000 description 1
- 208000010191 Osteitis Deformans Diseases 0.000 description 1
- 208000027868 Paget disease Diseases 0.000 description 1
- 208000006735 Periostitis Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 108091006629 SLC13A2 Proteins 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 206010046543 Urinary incontinence Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003263 anabolic agent Substances 0.000 description 1
- 229940124325 anabolic agent Drugs 0.000 description 1
- 239000002269 analeptic agent Substances 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 235000013871 bee wax Nutrition 0.000 description 1
- 239000012166 beeswax Substances 0.000 description 1
- SLUNEGLMXGHOLY-UHFFFAOYSA-N benzene;hexane Chemical compound CCCCCC.C1=CC=CC=C1 SLUNEGLMXGHOLY-UHFFFAOYSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033558 biomineral tissue development Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000037182 bone density Effects 0.000 description 1
- 210000002805 bone matrix Anatomy 0.000 description 1
- DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 1
- 230000002308 calcification Effects 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 235000011148 calcium chloride Nutrition 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 238000012754 cardiac puncture Methods 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 239000003240 coconut oil Substances 0.000 description 1
- 235000019864 coconut oil Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000001054 cortical effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- FMTDIUIBLCQGJB-SEYHBJAFSA-N demeclocycline Chemical compound C1([C@@H](O)[C@H]2C3)=C(Cl)C=CC(O)=C1C(=O)C2=C(O)[C@@]1(O)[C@@H]3[C@H](N(C)C)C(O)=C(C(N)=O)C1=O FMTDIUIBLCQGJB-SEYHBJAFSA-N 0.000 description 1
- 229960002398 demeclocycline Drugs 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000002224 dissection Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- QTTMOCOWZLSYSV-QWAPEVOJSA-M equilin sodium sulfate Chemical compound [Na+].[O-]S(=O)(=O)OC1=CC=C2[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4C3=CCC2=C1 QTTMOCOWZLSYSV-QWAPEVOJSA-M 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 150000004673 fluoride salts Chemical class 0.000 description 1
- 150000002222 fluorine compounds Chemical class 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012737 fresh medium Substances 0.000 description 1
- 210000002454 frontal bone Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000004349 growth plate Anatomy 0.000 description 1
- BCQZXOMGPXTTIC-UHFFFAOYSA-N halothane Chemical compound FC(F)(F)C(Cl)Br BCQZXOMGPXTTIC-UHFFFAOYSA-N 0.000 description 1
- 229960003132 halothane Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000008750 humoral hypercalcemia of malignancy Diseases 0.000 description 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical compound [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 description 1
- 229910052588 hydroxylapatite Inorganic materials 0.000 description 1
- 230000001184 hypocalcaemic effect Effects 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 208000027202 mammary Paget disease Diseases 0.000 description 1
- 210000004373 mandible Anatomy 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 230000008693 nausea Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 229960002378 oftasceine Drugs 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 210000003455 parietal bone Anatomy 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 1
- 201000001245 periodontitis Diseases 0.000 description 1
- 210000003460 periosteum Anatomy 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000008288 physiological mechanism Effects 0.000 description 1
- 230000007505 plaque formation Effects 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 238000005096 rolling process Methods 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 229910000077 silane Inorganic materials 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000011775 sodium fluoride Substances 0.000 description 1
- 235000013024 sodium fluoride Nutrition 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- ICSAXRANXQSPQP-VUKDEKJYSA-M sodium;(5r,6s)-6-[(1r)-1-hydroxyethyl]-7-oxo-3-[(2r)-oxolan-2-yl]-4-thia-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylate Chemical compound [Na+].S([C@@H]1[C@H](C(N1C=1C([O-])=O)=O)[C@H](O)C)C=1[C@H]1CCCO1 ICSAXRANXQSPQP-VUKDEKJYSA-M 0.000 description 1
- 238000004611 spectroscopical analysis Methods 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000000623 ulna Anatomy 0.000 description 1
- 238000002211 ultraviolet spectrum Methods 0.000 description 1
- 230000001457 vasomotor Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- ORZHVTYKPFFVMG-UHFFFAOYSA-N xylenol orange Chemical compound OC(=O)CN(CC(O)=O)CC1=C(O)C(C)=CC(C2(C3=CC=CC=C3S(=O)(=O)O2)C=2C=C(CN(CC(O)=O)CC(O)=O)C(O)=C(C)C=2)=C1 ORZHVTYKPFFVMG-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
- C07J1/0051—Estrane derivatives
- C07J1/0059—Estrane derivatives substituted in position 17 by a keto group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J15/00—Stereochemically pure steroids containing carbon, hydrogen, halogen or oxygen having a partially or totally inverted skeleton, e.g. retrosteroids, L-isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/224,849 US5395831A (en) | 1994-04-08 | 1994-04-08 | Treating cardiac disorders with Δ9(11)-dehydro-8-isoestrone |
| US224849 | 1994-04-08 | ||
| PCT/US1995/004252 WO1995027724A1 (en) | 1994-04-08 | 1995-04-06 | An equilin double bond isomer from the acid isomerization of equilin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2242195A AU2242195A (en) | 1995-10-30 |
| AU688029B2 true AU688029B2 (en) | 1998-03-05 |
Family
ID=22842497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU22421/95A Ceased AU688029B2 (en) | 1994-04-08 | 1995-04-06 | An equilin double bond isomer from the acid isomerization of equilin |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US5395831A (enExample) |
| EP (1) | EP0754190B1 (enExample) |
| JP (1) | JPH09511748A (enExample) |
| KR (1) | KR970702291A (enExample) |
| CN (1) | CN1149298A (enExample) |
| AT (1) | ATE177111T1 (enExample) |
| AU (1) | AU688029B2 (enExample) |
| CA (1) | CA2186486A1 (enExample) |
| DE (1) | DE69508068T2 (enExample) |
| DK (1) | DK0754190T3 (enExample) |
| ES (1) | ES2128051T3 (enExample) |
| GR (1) | GR3030185T3 (enExample) |
| HU (1) | HUT76338A (enExample) |
| IL (1) | IL113178A (enExample) |
| NZ (1) | NZ283951A (enExample) |
| TW (1) | TW314468B (enExample) |
| WO (1) | WO1995027724A1 (enExample) |
| ZA (1) | ZA952771B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5395831A (en) * | 1994-04-08 | 1995-03-07 | American Home Products Corporation | Treating cardiac disorders with Δ9(11)-dehydro-8-isoestrone |
| AU7013296A (en) * | 1995-08-30 | 1997-03-19 | Eli Lilly And Company | N-butylsulfonate esters of estrogens |
| ZA968873B (en) | 1995-11-06 | 1997-05-28 | Akzo Nobel Nv | Isomerisation of equillin |
| US5998639A (en) * | 1995-11-06 | 1999-12-07 | Akzo Nobel, N.V. | Sulfatation of estrogen mixtures |
| AU703814B2 (en) * | 1995-12-04 | 1999-04-01 | Wyeth | Antioxidant |
| EP0785212A1 (en) * | 1996-01-22 | 1997-07-23 | Laboratoire Theramex | New 19-nor-pregnene derivatives |
| ID18256A (id) * | 1996-09-16 | 1998-03-19 | American Home Prod | Penggunaan dari 8,9-dehidro estron sebagai estrogen dengan hasil netral pada tingkat prolaktin |
| IL124213A (en) * | 1997-05-02 | 2004-12-15 | Akzo Nobel Nv | Sulfation of estrogen mixtures |
| DE19723794A1 (de) * | 1997-06-06 | 1998-12-10 | Jenapharm Gmbh | Nichtestrogene Derivate des Estradiols mit antioxidativer Aktivität |
| US5866561A (en) * | 1997-08-21 | 1999-02-02 | Scimed Life Systems, Inc. | Local delivery of estrogen for angiogenesis |
| GB9817623D0 (en) * | 1998-08-13 | 1998-10-07 | Glaxo Group Ltd | Pharmaceutical compounds |
| EP1330467B1 (en) | 2000-11-03 | 2007-05-02 | Washington University | Modified, hydroxy-substituted aromatic structures having cytoprotective activity |
| US20020132802A1 (en) * | 2000-11-17 | 2002-09-19 | Washington Univeristy | Cytoprotective polycyclic compounds |
| US20030158432A1 (en) * | 2002-01-08 | 2003-08-21 | Leonard Thomas W. | Synthesis of a mixture of sulfated estrogens using a sulfur trioxide complex |
| US6855735B2 (en) | 2002-03-20 | 2005-02-15 | Temple University Of The Commonwealth System Of Higher Education | Ketamine treatment of restless legs syndrome |
| WO2003084978A1 (en) * | 2002-04-01 | 2003-10-16 | University Of Florida | Steroidal quinols as prodrugs of antioxidants |
| US20070213310A1 (en) * | 2002-04-01 | 2007-09-13 | Laszlo Prokai | Prodrugs for Use as Ophthalmic Agents |
| US7300926B2 (en) * | 2002-04-01 | 2007-11-27 | University Of Florida Research Foundation, Inc. | Steroidal quinols and their use for estrogen replacement therapy |
| US7186707B2 (en) | 2002-04-01 | 2007-03-06 | University Of Florida | Prodrugs for use as ophthalmic agents |
| US20240183014A1 (en) | 2022-12-03 | 2024-06-06 | Arthur Craig Reardon | High Speed Steel Composition |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE205169C (enExample) * | ||||
| US3394153A (en) * | 1965-08-18 | 1968-07-23 | Merck & Co Inc | Process for the preparation of d, 1-8-dehydroestrone, and intermediates obtained therefrom |
| US3391170A (en) * | 1965-09-21 | 1968-07-02 | Smith | 13-alkylogona-1, 3, 5 (10), 9 (11)-tetraenes |
| US3385872A (en) * | 1966-08-29 | 1968-05-28 | Syntex Corp | Process for the preparation of 3-hydroxy-19-nor-delta1, 3, 5(10), 9(11)-tetraene steroids |
| US3471528A (en) * | 1968-02-21 | 1969-10-07 | Lilly Co Eli | Method for producing delta**9(11) unsaturation in estrone and related compound |
| US3542819A (en) * | 1968-06-11 | 1970-11-24 | American Home Prod | Process for preparing 8-isoestrone |
| US3649621A (en) * | 1969-12-19 | 1972-03-14 | American Home Prod | Novel 3-cyclopentyl ethers of 13-alkylgon-poly-enes |
| US3689512A (en) * | 1970-10-06 | 1972-09-05 | American Home Prod | Novel 3-etherified-1,3,5(10)-triene-steroids and process thereof |
| DE3014120A1 (de) * | 1980-04-12 | 1981-10-29 | Hoechst Ag, 6000 Frankfurt | Verfahren zur synthese von oestron bzw. oestronderivaten |
| DD205169A1 (de) * | 1982-05-26 | 1983-12-21 | Adw Ddr | Verfahren zur herstellung von 9(11)-dehydro-oestra-1,3,5(10)-trienen |
| US5210081A (en) * | 1992-02-26 | 1993-05-11 | American Home Products Corporation | Alkali metal 8,9-dehydroestrone sulfate esters |
| US5395831A (en) * | 1994-04-08 | 1995-03-07 | American Home Products Corporation | Treating cardiac disorders with Δ9(11)-dehydro-8-isoestrone |
-
1994
- 1994-04-08 US US08/224,849 patent/US5395831A/en not_active Expired - Lifetime
- 1994-12-01 US US08/347,742 patent/US5496814A/en not_active Expired - Lifetime
-
1995
- 1995-02-20 TW TW084101526A patent/TW314468B/zh active
- 1995-03-29 IL IL11317895A patent/IL113178A/xx not_active IP Right Cessation
- 1995-04-04 ZA ZA952771A patent/ZA952771B/xx unknown
- 1995-04-06 DE DE69508068T patent/DE69508068T2/de not_active Expired - Fee Related
- 1995-04-06 DK DK95915579T patent/DK0754190T3/da active
- 1995-04-06 KR KR1019960705688A patent/KR970702291A/ko not_active Ceased
- 1995-04-06 CN CN95193322A patent/CN1149298A/zh active Pending
- 1995-04-06 CA CA002186486A patent/CA2186486A1/en not_active Abandoned
- 1995-04-06 WO PCT/US1995/004252 patent/WO1995027724A1/en not_active Ceased
- 1995-04-06 AU AU22421/95A patent/AU688029B2/en not_active Ceased
- 1995-04-06 EP EP95915579A patent/EP0754190B1/en not_active Expired - Lifetime
- 1995-04-06 HU HU9602755A patent/HUT76338A/hu unknown
- 1995-04-06 NZ NZ283951A patent/NZ283951A/en unknown
- 1995-04-06 JP JP7526442A patent/JPH09511748A/ja not_active Withdrawn
- 1995-04-06 AT AT95915579T patent/ATE177111T1/de not_active IP Right Cessation
- 1995-04-06 ES ES95915579T patent/ES2128051T3/es not_active Expired - Lifetime
- 1995-05-25 US US08/450,960 patent/US5552395A/en not_active Expired - Lifetime
-
1999
- 1999-05-11 GR GR990401273T patent/GR3030185T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP0754190B1 (en) | 1999-03-03 |
| EP0754190A1 (en) | 1997-01-22 |
| HUT76338A (en) | 1997-08-28 |
| DE69508068T2 (de) | 1999-10-28 |
| US5496814A (en) | 1996-03-05 |
| WO1995027724A1 (en) | 1995-10-19 |
| JPH09511748A (ja) | 1997-11-25 |
| ATE177111T1 (de) | 1999-03-15 |
| GR3030185T3 (en) | 1999-08-31 |
| TW314468B (enExample) | 1997-09-01 |
| IL113178A0 (en) | 1995-06-29 |
| US5395831A (en) | 1995-03-07 |
| HU9602755D0 (en) | 1996-11-28 |
| CN1149298A (zh) | 1997-05-07 |
| ES2128051T3 (es) | 1999-05-01 |
| CA2186486A1 (en) | 1995-10-19 |
| KR970702291A (ko) | 1997-05-13 |
| DE69508068D1 (de) | 1999-04-08 |
| IL113178A (en) | 2000-07-26 |
| DK0754190T3 (da) | 1999-09-27 |
| AU2242195A (en) | 1995-10-30 |
| NZ283951A (en) | 1998-07-28 |
| ZA952771B (en) | 1996-10-04 |
| US5552395A (en) | 1996-09-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU688029B2 (en) | An equilin double bond isomer from the acid isomerization of equilin | |
| DE60025817T2 (de) | Ent-steroide als selektiv wirksame estrogene | |
| EP0639970B2 (en) | Contraception method using competitive progesterone antagonists and novel compounds useful therein | |
| KR100243537B1 (ko) | 에스트라-1,3,5(10)-트리엔 유도체를 함유한 약제학적 조성물 | |
| US7081477B2 (en) | Estrogenic compounds as anti-mitotic agents | |
| JPH09501433A (ja) | 抗−分裂剤としてのエストロゲン性化合物 | |
| JPH07508264A (ja) | 免疫系の調節 | |
| JP2000355598A (ja) | ステロイドスルファターゼインヒビター | |
| CN1383381A (zh) | 一种含有五羟黄酮衍生物活性成分的骨质疏松症治疗剂 | |
| EP2953959A1 (en) | 16- and 17- deuterated estrogen-3-sulfamates as estrogenic agents | |
| RU2159774C2 (ru) | Производные сульфамата, способ их получения и фармацевтические составы | |
| EP0614896B1 (en) | Esculetin derivatives and pharmaceutical composition | |
| EP1226155B1 (de) | 18-nor-steroide als selektiv wirksame estrogene | |
| EP0894000B1 (en) | Use for delivering estrogen | |
| JPH01197438A (ja) | 更年期障害およびホルモン依存性腫瘍の治療用ならびに避妊薬として使用するための医薬調剤およびその製法 | |
| CN1668310A (zh) | 使用结合型雌激素和曲美孕酮的联合给药形式的激素替代疗法 | |
| JPH03294230A (ja) | 子宮内膜症治療剤 | |
| DE10226326A1 (de) | 9-alpha-substiuierte Estratriene als selektiv wirksame Estrogene | |
| EP0850647B1 (fr) | Application de composés stéroides substitués en ll pour la fabrication de médicaments ayant une activité estrogène dissociée | |
| CN1668309A (zh) | 用于治疗绝经后疾病的曲美孕酮和雌激素 | |
| RU2136275C1 (ru) | Фармацевтическая композиция, ингибирующая костную резорбцию или промотирующая остеогенез | |
| RU2294332C2 (ru) | Стероидное соединение, его применение и способ лечения | |
| JPH0769883A (ja) | アロマターゼ阻害剤 | |
| Dinchuk et al. | Effects of estramustine and megestrol on ultrastructure of rat ventral prostate | |
| Sergeev et al. | Impact of 8-isoestrone analogs on estradiol binding in uterine tissue from ovariectomized rats |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HB | Alteration of name in register |
Owner name: WYETH Free format text: FORMER NAME WAS: AMERICAN HOME PRODUCTS CORPORATION |
|
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |